Geron Corporation (GERN): Price and Financial Metrics

Geron Corporation (GERN): $1.45

-0.01 (-0.68%)

POWR Rating

Component Grades













Add GERN to Watchlist
Sign Up

Industry: Biotech


of 509

in industry


  • Sentiment is the dimension where GERN ranks best; there it ranks ahead of 61.41% of US stocks.
  • GERN's strongest trending metric is Growth; it's been moving down over the last 52 weeks.
  • GERN's current lowest rank is in the Value metric (where it is better than 12.76% of US stocks).

GERN Stock Summary

  • Geron Corp's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than merely 6.68% of US listed stocks.
  • With a price/sales ratio of 1,164.37, Geron Corp has a higher such ratio than 99.41% of stocks in our set.
  • With a year-over-year growth in debt of 581.46%, Geron Corp's debt growth rate surpasses 97.69% of about US stocks.
  • Stocks that are quantitatively similar to GERN, based on their financial statements, market capitalization, and price volatility, are ARDS, CKPT, ATNM, MCRB, and CLLS.
  • Visit GERN's SEC page to see the company's official filings. To visit the company's web site, go to

GERN Valuation Summary

  • GERN's price/sales ratio is 1156.5; this is 30334.21% higher than that of the median Healthcare stock.
  • Over the past 243 months, GERN's price/sales ratio has gone up 1098.9.
  • GERN's EV/EBIT ratio has moved up 6.1 over the prior 243 months.

Below are key valuation metrics over time for GERN.

Stock Date P/S P/B P/E EV/EBIT
GERN 2021-08-31 1156.5 2.6 -4.6 -4.5
GERN 2021-08-30 1148.5 2.6 -4.6 -4.5
GERN 2021-08-27 1132.6 2.6 -4.5 -4.4
GERN 2021-08-26 1076.6 2.5 -4.3 -4.2
GERN 2021-08-25 1084.6 2.5 -4.3 -4.2
GERN 2021-08-24 1044.8 2.4 -4.2 -4.1

GERN Growth Metrics

  • Its year over year revenue growth rate is now at -25.71%.
  • Its 2 year price growth rate is now at -55.65%.
  • Its year over year net cashflow from operations growth rate is now at -27.77%.
Over the past 67 months, GERN's revenue has gone down $35,969,000.

The table below shows GERN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 0.402 -78.611 -100.836
2021-03-31 0.338 -73.192 -87.086
2020-12-31 0.253 -66.652 -75.617
2020-09-30 0.374 -64.404 -80.9
2020-06-30 0.397 -60.935 -76.429
2020-03-31 0.455 -57.285 -74.844

GERN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • GERN has a Quality Grade of C, ranking ahead of 51.69% of graded US stocks.
  • GERN's asset turnover comes in at 0.002 -- ranking 425th of 681 Pharmaceutical Products stocks.
  • ZTS, NSTG, and NEOG are the stocks whose asset turnover ratios are most correlated with GERN.

The table below shows GERN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.002 1 -0.424
2021-03-31 0.001 1 -0.352
2020-12-31 0.001 1 -0.350
2020-09-30 0.002 1 -0.448
2020-06-30 0.002 1 -0.503
2020-03-31 0.003 1 -0.589

GERN Price Target

For more insight on analysts targets of GERN, see our GERN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.20 Average Broker Recommendation 1.4 (Strong Buy)

GERN Stock Price Chart Interactive Chart >

Price chart for GERN

GERN Price/Volume Stats

Current price $1.45 52-week high $2.36
Prev. close $1.46 52-week low $1.20
Day low $1.42 Volume 1,062,300
Day high $1.47 Avg. volume 4,496,820
50-day MA $1.38 Dividend yield N/A
200-day MA $1.51 Market Cap 464.87M

Geron Corporation (GERN) Company Bio

Geron Corporation focuses on the development of telomerase inhibitor, imetelstat, for treating hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.

GERN Latest News Stream

Event/Time News Detail
Loading, please wait...

GERN Latest Social Stream

Loading social stream, please wait...

View Full GERN Social Stream

Latest GERN News From Around the Web

Below are the latest news stories about Geron Corp that investors may wish to consider to help them evaluate GERN as an investment opportunity.

Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

FOSTER CITY, Calif., October 21, 2021--Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Yahoo | October 21, 2021

Geron Announces Completion of Patient Enrollment in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes

FOSTER CITY, Calif., October 18, 2021--Geron Corporation (Nasdaq: GERN), a late-stage biopharmaceutical company focused on the development and commercialization of treatments for hematologic malignancies, today announced the completion of patient enrollment in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class telomerase inhibitor, in lower risk myelodysplastic syndromes (MDS). Based upon current planning assumptions, Geron expects top-line results for IMerge Phase 3 to b

Yahoo | October 18, 2021

Geron to Host a Virtual Investor Event in November

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron to Host a Virtual Investor Event in November

Business Wire | October 15, 2021

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning, investor!

William White on InvestorPlace | October 12, 2021

Geron Announces Publication of Analyses Comparing Real World Data to IMbark Phase 2 in Annals of Hematology

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Announces Publication of Analyses Comparing Real World Data to IMbark Phase 2 in Annals of Hematology

Business Wire | October 11, 2021

Read More 'GERN' Stories Here

GERN Price Returns

1-mo 5.84%
3-mo 16.94%
6-mo -4.61%
1-year -23.28%
3-year -4.61%
5-year -29.61%
YTD -8.81%
2020 16.91%
2019 36.00%
2018 -44.44%
2017 -13.04%
2016 -57.23%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8899 seconds.